Biomarker Type: Proteomic
-
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
-
The serum-based VeriStrat test is associated with proinflammatory reactants and clinical outcomes in non-small cell lung cancer patients
-
A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma
-
Development of Clinically Relevant Tests from Human Serum Samples: A Look at the Circulating Proteome
-
Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer with brain metastases
-
Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockadeImpact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
-
INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient management in early and locally advanced NSCLC
-
The Role Of Proteomic Testing in Improving Prognosis and Care Planning Quality Measures for Lung Cancer
-
Faster Turnaround Spurs Clinical Adoption of Liquid Biopsy Tests for Treating Non-Small Cell Lung Cancer
-
Tumor-Associated Autoantibodies: Re-Optimization of Nodify CDT Diagnostic Performance and its Application to Indeterminate Pulmonary Nodules